Suppression of lymphocyte function with breast carcinoma I-active glycopeptides
Abstract:
Patients with metastatic breast carcinoma (BCa) have defective peripheral blood lymphocyte (PBL) responsiveness to mitogenic and antigenic stimulation. In the following experiments, glycopeptides were isolated from the pronase digests of breast carcinoma tissue. After elution from Sephadex G-50, glycopeptides from BCa inhibited PBL responsiveness to mitogenic (PHA) stimulation. The glycopeptides contained blood group I-antigenic determinants. These experiments demonstrate the presence of blood group I-active peptides in breast carcinoma that suppress peripheral blood lymphocyte functions. Further studies are in progress.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...


